In-vitro activities of quinupristin/dalfopristin and other anti-staphylococcal agents against methicillin-resistant strains of Staphylococcus aureus isolated over a 16-year period
underscore the need both to identify alternative agents with activities against such bacteria and to maintain a constant vigil for the appearance of further strains resistant to currently available drugs. We report here the results of an investigation of the in-vitro activities of nine antimicrobials against 194 MR SA strains isolated in eight countries over a period of 16 years.
The 194 clonally unrelated, non-replicate isolates included 158 strains recovered between 1990 and 1996 from patients in G ermany as well as 36 strains (provided by H offmann La R oche, Basle, Switzerland) isolated between 1981 and 1989 from patients in the following seven countries: Japan (eight strains); Brazil (eight); Switzerland (six); Sri Lanka (four); Spain (four); U K (three); and H ungary (three). A ll of the isolates, which were selected from a larger collection on the basis that they belonged to different pulsed-field gel electrophoretic types, 5 were screened for the presence of m ecA and coa genes by a multiplex PCR . The antibiotics tested were vancomycin, teicoplanin, quinupristin/dalfopristin, gentamicin, amikacin, ciprofloxacin, ofloxacin, sparfloxacin and moxifloxacin (BA Y 12-8039). MICs were determined by a microbroth dilution method according to guidelines recommended by the National Committee for Clinical Laboratory Standards (NCCLS); 6 the inoculum was approximately 10 8 cfu/L. D espite the development of low-level glycopeptide resistance in clinical isolates of coagulase-negative staphylococci and recent reports of MR SA strains with reduced susceptibilities to vancomycin, 3, 4 all of the strains isolated over the 16 year period were susceptible to the glycopeptides, vancomycin and teicoplanin, with MICs ranging from 0.125 to 4 mg/L and from 0.06 to 2 mg/L respectively (Table) . For the time being, therefore, these antibiotics will continue to be the drugs of choice for the treatment of patients with MR SA infections. 2 The combination of quinupristin and dalfopristin (Synercid) was also active in vitro against 100% of the isolates tested, with MICs ranging from 0.06 to 2 mg/L and a MIC 90 of 1 mg/L (Table) . A s quinupristin and dalfopristin are weak inducers of the erm gene, which encodes a methylase that inactivates erythromycin and other antibiotics belonging to the MLS group, the combination is active against strains exhibiting inducible MLS B resistance and therefore represents a promising alternative to the glycopeptides. H owever, it will be necessary to monitor the emergence of resistance to this agent during therapy and to evaluate its role, either alone or combined with other anti-staphylococcal antibiotics, as treatment of patients with MR SA infections.
O f the MR SA strains tested, 79% were resistant to gentamicin (MIC 90 128 mg/L), whilst only 21% were resistant to amikacin (MIC 90 64 mg/L) (Table) . A minoglycosides are not normally recommended as monotherapy of patients with staphylococcal infections, although synergy may be obtained when one of these drugs is combined with vancomycin, e.g. in patients with staphylococcal endocarditis. 7 Moxifloxocin was the most active of the fluoroquinolones tested, followed by sparfloxacin, ofloxacin and c i p r o floxacin (MIC 9 0 s of 1, 8, 64 and 128 mg/L respectively) (Table) . A s cross-resistance is a characteristic of these antibiotics, there is uncertainty about the efficacies of the 663 8 In summary, all 194 MR SA isolates tested in the present study were susceptible to vancomycin, teicoplanin and quinupristin/dalfopristin. The novel fluoroquinolone, moxifloxacin, was also shown to be highly active in vitro and combination regimens that include this agent may be appropriate when reduced susceptibility or intolerance to a glycopeptide prevents the administration of drugs belonging to this group.
